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Sepsis and septic shock are complex and thera-
peutically challenging disorders of the immune 
system. Organ dysfunction during sepsis is a life-
threatening and extremely cost-intensive clini-
cal problem aff  ecting  600,000 patients annually 
in the United States, with an associated mortal-
ity rate ranging from 20 to 60% (1–3). Despite 
tremendous research eff  orts over the last 20 yr, 
sepsis remains the leading cause of death in 
  intensive care units. With the exception of 
  recombinant-activated protein C therapy, the 
treatment of septic patients remains largely sup-
portive because many pathophysiological organ 
level changes are not well understood; specifi  c 
therapies are therefore not available.
Cardiac dysfunction often develops in pa-
tients with sepsis and is referred to as “septic 
cardiomyopathy.” Clinically, sepsis is a bipha-
sic process in which patients initially exhibit a 
hyperdynamic phase (increased cardiac output 
and tissue perfusion, decreased total vascular 
resistance) followed by a hypodynamic phase 
(decreased cardiac output, reduced tissue mi-
crovascular fl  ow, and increased peripheral vas-
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cular resistance) (4). Myocardial dysfunction is 
common for patients with sepsis. Numerous 
clinical and experimental studies show revers-
ible biventricular dilatation, decreased ejection 
fraction, and decreased response to fl  uid resus-
citation and catecholamine stimulation during 
the hypodynamic phase (5). Most importantly, 
myocardial dysfunction puts septic patients at 
high risk to develop multi-organ failure, which 
is associated with a high mortality. Multi-organ 
failure results from a “vicious cycle” initiated 
by impaired cardiac function, decreased cardiac 
output leading to compromised tissue/organ 
perfusion, decreased oxygen and nutrient sup-
ply, ischemia, organ dysfunction, and a hypo-
reactive immune system (6). Therefore, cardiac 
dysfunction plays a pivotal role and is often de-
cisive in determining survival or death.
In light of the multifactorial pathogenesis 
of sepsis and septic shock, extensive work has 
been done to characterize the numerous agents 
and mediators that could cause myocardial dys-
function (7–13). A “myocardial depressant sub-
stance” in the serum of septic patients has been 
proposed to account for the cardiac dysfunc-
tion observed during the hypodynamic phase 
of sepsis (7). Activation of the   complement 
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Defective cardiac function during sepsis has been referred to as “cardiomyopathy of sepsis.” 
It is known that sepsis leads to intensive activation of the complement system. In the 
current study, cardiac function and cardiomyocyte contractility have been evaluated in rats 
after cecal ligation and puncture (CLP). Signifi  cant reductions in left ventricular pressures 
occurred in vivo and in cardiomyocyte contractility in vitro. These defects were prevented 
in CLP rats given blocking antibody to C5a. Both mRNA and protein for the C5a receptor 
(C5aR) were constitutively expressed on cardiomyocytes; both increased as a function of 
time after CLP. In vitro addition of recombinant rat C5a induced dramatic contractile 
dysfunction in both sham and CLP cardiomyocytes, but to a consistently greater degree in 
cells from CLP animals. These data suggest that CLP induces C5aR on cardiomyocytes and 
that in vivo generation of C5a causes C5a–C5aR interaction, causing dysfunction of 
cardiomyocytes, resulting in compromise of cardiac performance.
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  system is a hallmark of sepsis that leads to robust generation 
of potent   proinfl  ammatory complement factors. Among those 
factors, C5a is one of the most potent infl  ammatory peptides 
(14–17). There is accumulating evidence that C5a–C5a re-
ceptor (C5aR) signaling plays an essential role in septic shock 
(18). In earlier work, we demonstrated that blockade of   either 
C5a or C5aR greatly improves survival in sepsis   after cecal li-
gation and puncture (CLP) in rodents (19, 20). Furthermore, 
we have demonstrated that anti-C5a treatment resulted in 
decreased levels of bacteremia, preservation of innate   immune 
functions of blood neutrophils, greatly reduced thymocyte 
apoptosis, and improvement in the overall survival in the rat 
model of CLP-induced sepsis (19–22).
The contribution of the complement system to septic 
cardiomyopathy has not been studied. Recently, we showed 
that C5aR expression is signifi  cantly elevated in whole heart 
homogenates (based on in vivo binding studies of anti-C5aR 
IgG and immunostaining), perhaps setting the stage for C5a-
induced organ dysfunction (23). However, the expression of 
C5aR on the cell surface of cardiomyocytes has not been de-
termined. The present study was designed to evaluate the 
impact of C5a and C5a blockade on septic cardiac dysfunc-
tion both in vivo and in vitro. To investigate the eff  ects of 
anti-C5a on preventing cardiomyocyte contractility defi  cits, 
we used the rat sepsis model (CLP) to examine in vivo left 
ventricular function and in vitro single cardiomyocyte sarco-
mere contractile performance.
RESULTS
Expression of C5aR on cardiomyocytes
Both mRNA and protein for C5aR were measured in cardio-
myocytes from sham rats and CLP rats as a function of time 
after surgery. As shown in Fig. 1, mRNA for C5aR in extracts 
of cardiomyocytes from CLP rats showed progressive increases 
12, 24, and 48 h after CLP, whereas any changes in C5aR 
mRNA in sham cardiomyocytes were much less evident. [ID]FIG1[/ID] 
When homogenates from cardiomyocytes were evaluated by 
Western blot analysis, there were progressive increases 6–48 h 
after CLP (Fig. 2).[ID]FIG2[/ID] Cardiomyocytes from sham surgery rats 
showed no increases in C5aR expression (unpublished data).
The studies were extended by the rise of immunostaining 
of cardiomyocytes for C5aR protein (Fig. 3). [ID]FIG3[/ID] Confocal im-
munostaining revealed intense cortical staining in cardiomyo-
cytes 12 h after CLP (Fig. 3 A), whereas cells obtained from 
sham animals show evidence of constitutive expression (Fig. 
3 B) that was much less intense. Surface immunostaining of 
individual cardiomyocytes for C5aR proteins revealed intense 
staining of cardiomyocytes obtained 12 h after CLP (Fig. 3 C) 
and much less staining of sham cardiomyocytes (Fig. 3 D), 
consistent with the confocal staining data. When irrelevant 
rabbit IgG was used, there was very little staining of either 
CLP or sham (Fig. 3, E and F) cardiomyocytes, respectively.
Reduced left ventricular pressure (LVP) in septic animals 
and functional preservation by in vivo C5a blockade
LVP was recorded in CLP and sham-operated rats treated 
with either anti-C5a or an equivalent amount of nonspecifi  c 
IgG. The results are shown in Fig. 4. [ID]FIG4[/ID] Rats subjected to 
CLP developed signifi  cantly lower mean LVPs than their 
sham-treated counterparts (P < 0.001, analysis of variance 
[ANOVA]) (Fig. 4 A). Antibody-induced in vivo blockade 
of C5a, which was given intravenously immediately after 
CLP, resulted in greatly improved mean, maximum, and 
minimum LVPs (LVPmean, LVPmax, LVPmin ) when compared 
with septic rats treated with nonspecifi  c IgG (P < 0.001, 
ANOVA). Injection of either anti-C5a or preimmune IgG 
into sham rats had no eff  ect on LVP values. No diff  erences 
were found in measured heart rates between the various 
groups (unpublished data). These data indicate that in vivo 
myocardial dysfunction is abolished by blockade of C5a in 
septic animals when compared with sham animals. Whether 
the mean LVP, the maximum LVP, or the minimum LVP 
values were used, the results were the same in all cases.
Evidence for C5a-dependent cardiomyocyte dysfunction 
after CLP
We next investigated whether polymicrobial sepsis (CLP) 
infl  uences cardiomyocyte sarcomere contractility. Baseline 
sarcomere length values did not diff  er signifi  cantly among all 
Figure 1.  Time course after sham surgery or CLP for cardiomyocyte 
expression of C5aR mRNA, using homogenates of cardiomyocytes. 
Real-time PCR was used. Data are presented as ratios of C5aR/GADPH. 
Data are representative of two independent experiments.
Figure 2.  Western blots for C5aR protein content in cardiomyo-
cyte homogenates from CLP or sham surgery rats as a function of 
time after surgery. Data are expressed as ratios of C5aR protein to 
GAPDH protein. Representative gel patterns (from two independent 
  experiments) are shown (bottom).JEM VOL. 203, January 23, 2006  55
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cardiomyocytes analyzed. Cardiomyocytes from CLP-  injured 
animals demonstrated an  50% decrease in relative peak sar-
comere shortening compared with sham animals (peak height 
CLP + nonspecifi  c IgG 0.099 ± 0.005 μm vs. sham 0.201 ± 
0.008 μm, P < 0.001, ANOVA, Fig. 5 A). [ID]FIG5[/ID]
Analysis of single cell cardiomyocyte sarcomere shorten-
ing revealed a substantial improvement in peak shortening of 
cells isolated from CLP animals treated with anti-C5a com-
pared with CLP treated with nonspecifi  c IgG (peak height 
CLP + anti-C5a IgG, 0.168 ± 0.007 µm vs. CLP + nonspe-
cifi  c IgG, 0.086 ± 0.005 µm, P < 0.001, ANOVA, Fig. 
5 A). To assess whether the eff  ects of anti-C5a were injury 
dependent, we also included a group of rats that underwent 
sham operation and received the blocking antibody intrave-
nously. Relative peak sarcomere shortening values were not 
diff  erent after administration of IgG or anti-C5a in sham ani-
mals (Fig. 5 A). These results demonstrate that the presence 
of C5a, which is generated during sepsis, is linked to cardio-
myocyte dysfunction of CLP.
In addition to relative peak sarcomere shortening, nor-
malized maximum contraction and relaxation velocities were 
determined. Interestingly, infusion of anti-C5a greatly im-
proved the maximum velocities of contraction (−dL/dt) and 
relaxation (+dL/dt) comparable to those measured in sham 
animals (Fig. 5, B and C). Cardiomyocytes from CLP + anti-
C5a animals contracted signifi   cantly faster than animals 
treated with nonspecifi   c IgG (CLP + anti-C5a 27.98 ± 
0.92 s−1 vs. CLP + nonspecifi  c IgG 22.68 ± 0.41 s−1, P < 
0.001, ANOVA) (Fig. 5 B). Similar results were obtained for 
values of relaxation velocities +dL/dt (Fig. 5 C). Cardiomy-
ocytes derived from CLP + anti-C5a animals exhibited sig-
nifi  cantly faster relaxation velocity than cells isolated from 
CLP + IgG animals (CLP + anti-C5a 24.35 ± 0.91 s−1 vs. 
CLP  + nonspecifi   c IgG 18.58 ± 0.42 s−1, P < 0.001, 
ANOVA). Furthermore, maximum contraction and relax-
ation velocities occurred signifi  cantly earlier in CLP animals 
treated with anti-C5a than in rats infused with nonspecifi  c 
IgG (Fig. 5, D and E). These data indicate that CLP induces 
C5a-dependent dysfunction in cardiomyocytes and that block-
ade of C5a reverses these changes.
Time-dependent changes in cardiomyocytes contractility 
after CLP
Cardiomyocytes were obtained as a function of time after 
sham surgery or after CLP, as described in Fig. 6.[ID]FIG6[/ID] As shown 
in Fig. 6 A, contractility values in the sham cardiomyocytes 
not otherwise treated were essentially stable as a function 
of time (0–48 h after sham surgery). In striking contrast, as 
shown in Fig. 6 B, there was a progressive decrease in sar-
comere shortening 6, 12, and 24 h after CLP, with a slight 
  improvement at 48 h. When sham cardiomyocytes were ex-
posed to either 5.0 or 10.0 nM recombinant rat (rr)C5a, 
there was a progressive lost of contractility, with an  30% 
reduction in contractility after incubation with 5.0 nM C5a 
and a 53% reduction after exposure to 10.0 nM C5a. In the 
case of CLP cardiomyocytes, as shown in Fig. 6 B, there was 
a very substantial loss of contractility which was progressive 
with time up to 24 h after CLP. The addition of 5.0 nM of 
Figure 3.  C5aR protein expression visualized by confocal fl  uores-
cent microscopy (A and B) and immunohistochemical staining (C–F) 
12 h after CLP or sham operation. Typical staining for C5aR protein on 
the cardiomyocyte surface is shown for CLP (A) and sham cardiomyocytes 
(B). Immunohistochemical enface staining of cardiomyocytes using light 
microscopy (brown stain) confi  rmed the presence of C5aR protein on 
cardiomyocytes from CLP (C) and sham animals (D). Irrelevant rabbit IgG 
showed little staining in CLP (E) or sham cardiomyocytes (F). Figures are 
representative of two separate and independent experiments (60×).
Figure 4.  In vivo measurements of the following LVPs: mean 
(LVPmean, A), maximum (LVPmax, B), and minimum (LVPmin, C) 24 h 
  after CLP or sham operation. Anti-C5a or nonspecifi  c IgG was injected at 
the time of surgery. *, P < 0.001 (ANOVA). Each bar refl  ects several n = 5 rats.56   ROLE OF C5A IN SEPTIC CARDIAC DYSFUNCTION | Niederbichler et al.
C5a caused further reductions and greater reductions oc-
curred with exposure to 10.0 nM C5a. Thus, it appears that 
both sham cardiomyocytes as well as CLP cardiomyocytes 
show adverse eff  ects after exposure to C5a, but with greater 
decrements in function in CLP cardiomyocytes.
Effects of duration of in vitro exposure of cardiomyocytes 
to C5a
For these studies, cardiomyocytes were isolated from sham 
rats as well as CLP rats 24 h after sham surgery or CLP. 
Thereafter, they were exposed in vitro to 10.0 nM C5a for 
0–60 min and the changes on contractility were measured 
immediately after the indicated exposure time. As shown in 
Fig. 6 C, with no exposure to C5a, the expected signifi  cant 
diff  erences in contractility between sham and CLP cardio-
myocytes were verifi  ed. In general, contractility measure-
ments diminished as a function of time of exposure to C5a, 
especially up to 30 min, seeming to approach a plateau there-
after. Thus, the eff  ects of C5a on induction of contractility 
defects in cardiomyocytes seem to require no more than an 
exposure time of 30 min.
In companion studies, sham or CLP cardiomyocytes were 
exposed to C5a for either 15 min or 3 h, followed by wash-
ing, and contractility measurements were performed. Similar 
to the data in Fig. 6, there were decrements in cardiomyo-
cyte contractility after exposure to C5a. There was no diff  er-
ence in the reductions in contractility in cardiomyocytes 
Figure 5.  In vitro measurements of peak sarcomere shortening 
values (µm) (A), normalized maximum contraction velocity (−dL/dt) 
(B), normalized maximum relaxation velocity (+dL/dt) (C), time to 
maximum contraction velocity (ms) (D), and time to maximum re-
laxation velocity (ms) (E) 24 h after CLP or sham operation. Anti-C5a 
or nonspecifi  c IgG was injected at the time of operation. Using IonWizard 
Software and the IonOptix Acquisition System, 10–15 sarcomeres were 
included in a rectangle-shaped region of interest and contractions were 
recorded for 75 s, averaged, and analyzed. Each bar refl  ects several n = 5 
rats; total number of analyzed cells, n = 649. *, P < 0.001 (ANOVA).
Figure 6.  Contractile responses of cardiomyocytes as a function of 
time (0–48 h) after (A) sham surgery or (B) CLP. Companion cultures 
were exposed to 5.0 or 10.0 nM rrC5a. Deterioration of contractile 
  responses of sham and CLP cardiomyocytes as a function of duration 
(0–60 min) of exposure of cells to 1 nM rrC5a (C). Immediately after the 
periods of exposure to C5a, cardiomyocytes were evaluated for contractile 
responses. For each time point indicated, ≥20 cells were evaluated.JEM VOL. 203, January 23, 2006  57
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exposed for only 15 min versus 3 h (unpublished data). These 
data suggest that the interaction of C5a with cardiomyocytes 
occurs rapidly and that removal of the C5a soon thereafter 
will not prevent the progressive loss in contractility.
DISCUSSION
The complement system and septic cardiomyopathy
During sepsis and septic shock, cardiac function is often im-
paired, placing the patient at risk for multi-organ dysfunction 
and eventual death. The complement system is activated dur-
ing sepsis, resulting in generation of potent proinfl  ammatory 
factors, which may contribute to impaired function of the im-
mune system and vital organs. To what extent complement 
activation products can be linked to cardiac dysfunction dur-
ing sepsis is not known. In an endotoxin shock model, C3 
defi   ciency was associated with a decreased left ventricular 
ejection fraction (24). The present study investigated possible 
protective eff  ects of blocking the potent complement acti-
vation product, C5a, on cardiac performance during experi-
mental sepsis. Our results demonstrate for the fi  rst time that 
the C5aR is expressed on the surface of single cardiomyocytes 
obtained from septic and sham animals. C5aR content was 
higher on CLP cardiomyocytes. Furthermore, we provide 
evidence that in vivo interception of C5a (with anti-C5a) 
given at the time of onset of CLP signifi  cantly improved car-
diac performance both in vivo (Fig. 4), as refl  ected by restored 
levels of LVP (LVPmean, LVPmax, LVPmin ), and in vitro as re-
fl   ected by signifi  cantly restored peak sarcomere shortening 
levels and improved contractile velocities (±dL/dt, Fig. 5).
The current literature provides evidence for complement 
activation in humans and animals with septic disorders based 
on elevated plasma levels of C3a, C4a, and C5a (14–17). Ex-
cessive generation of complement anaphylatoxin, C5a, and 
its interaction with C5aR induces a plethora of cellular stress 
response mechanisms such as the modulation of cytokine ex-
pression, apoptosis, and activation of the coagulation path-
way (22, 25–28). Previously, our laboratory showed that C5a 
generation during sepsis plays a key role in the regulation of 
various pathophysiologic changes that can be reversed by 
blockade of C5a (19, 20, 22). Anti-C5a treatment and com-
plement depletion with cobra venom factor led to an in-
creased oxygen extraction ratio and oxygen consumption in 
a porcine model of sepsis (29). Septic cardiomyopathy is a 
key pathophysiologic event during the course of sepsis and it 
frequently determines whether the patient survives or dies. 
Given the immense socioeconomic impact of sepsis in terms 
of morbidity, mortality, and cost to the health system (esti-
mated $16.7 billion per year), the development of novel 
therapeutic strategies for septic cardiomyopathy is clearly 
warranted (30).
Constitutive and up-regulated expression of C5aR
Western blotting (for C5aR protein) and real-time PCR 
(C5aR mRNA content) of cardiomyocyte lysates revealed 
characteristic bands indicating expression of C5aR on rat car-
diomyocytes. Constitutive expression of C5aR on cardio-
myocytes was found in both CLP and sham animals, but 
higher levels were seen in cardiomyocytes obtained from 
CLP rats. This is in contrast with our fi  ndings in neutro-
phils where surface C5aR expression on PMNs was down-
  regulated in septic animals compared with shams (20). These 
contrasting fi  ndings underline the polyfunctional properties 
of the C5a–C5aR system. The diff  erences in the C5aR status 
in blood neutrophils and cardiomyocytes after CLP may sim-
ply refl  ect a higher concentration of C5a in blood than in the 
extravascular compartment. The central role of the neutro-
phil for innate immune function necessitates the presence and 
activation of neutrophils in the face of invading microorgan-
isms. Interference in this system because of excessive C5a 
production has been shown to compromise host defenses 
(20). In contrast, constitutive expression of C5aR on the car-
diomyocyte surface ensures the rapid initiation of cellular 
stress response mechanisms (alteration of intracellular cal-
cium, etc.). When excessive C5a generation occurs as in sep-
sis, these potentially protective mechanisms may turn into 
detrimental derangements both at the functional and cellular 
level. Additional support for this hypothesis was obtained 
by in vitro incubation of cardiomyocytes with C5a. The dose 
of 10.0 nM dramatically impaired contractility parameters in 
cardiomyocytes after sham surgery (Fig. 6 A). These data cor-
relate with the serum levels of C5a found in septic humans, 
which have been shown to range between 1.0 and 15.0 nM 
(14, 15). Similarly, 10.0 nM C5a abolished the already im-
paired contraction of cardiomyocytes from septic animals 
(unpublished data).
In summary, we provide evidence for constitutive and 
enhanced expression of C5aR on rat cardiomyocytes, which 
underscores the functional importance of the C5a–C5aR sys-
tem. This may explain the early onset of septic myocardial 
dysfunction and suggests potential therapeutic options based 
on systemic interception of C5a or C5aR. Constitutive C5aR 
expression does not appear to be harmful under baseline 
physiological conditions.
Effect of C5a blockade on cardiac function in vivo
CLP reproduces many of the characteristics of polymicrobial 
sepsis found in humans (31). We investigated alterations in 
cardiac function during the hypodynamic phase of sepsis, 
which usually occurs 20–24 h after CLP (32), when hemo-
dynamic parameters are decreased (33). In animal models, 
sepsis-induced defi  cits in cardiac contractility have been con-
troversial. Decreased parameters of contractility indepen-
dent of preload and changes in the myocardial structure have 
been reported in ex vivo studies on Langendorff  -perfused 
hearts (34). In contrast, no changes of cardiac contractility pa-
rameters or myocardial ultrastructure were reported during 
the hypodynamic phase of sepsis (35). Using a rat CLP model, 
a reduction in cardiac contractility parameters such as LVP 
and ±dP/dt has been described previously (36). Our results 
demonstrate signifi  cantly lower LVP values in CLP animals 
compared with shams, suggesting severely impaired cardiac 
contractility in sepsis. We provide evidence that infusion of 58   ROLE OF C5A IN SEPTIC CARDIAC DYSFUNCTION | Niederbichler et al.
anti-C5a prevented impairment of LVP in vivo in CLP ani-
mals. Our cellular studies show that the interaction of C5a–
C5aR on cardiomyocytes is a major contributor to the 
reduced levels of LVP observed in vivo during sepsis. C5a 
and C3a have previously been shown to exert profound va-
sodilatative eff  ects on the systemic and coronary vasculature, 
which might exacerbate the myocardial contractile defi  cits in 
sepsis and partially explain the low systemic blood pressure 
values seen in septic humans and animal models (37, 38).
Using a functional analysis approach, we found that 
blockade of C5a–C5aR interaction led to a signifi  cant im-
provement of cardiac function, as refl  ected in restored mean 
LVP and max/min LVP values comparable to sham animals. 
These results support the importance of C5a–C5aR interac-
tion at the cardiomyocyte level in septic cardiomyopathy.
Effect of C5a blockade on cardiomyocyte function in vitro
A major fi  nding in the present study is that cardiomyocytes 
isolated from CLP animals exhibited signifi  cantly decreased 
sarcomere contractility parameters (peak sarcomere shorten-
ing, ±dL/dt) compared with sham animals. At the sarcomere 
level, our study showed myocellular contractile defi  cits dur-
ing CLP-induced sepsis. In our analysis, we used a standard-
ized area that included at least 15–20 sarcomeres and acquired 
real-time sarcomere-shortening values. This technique is sar-
comere specifi  c and independent of cell size compared with 
the cellular edge detection shortening measurement used in a 
prior study (39).
We sought to determine the role of C5a toward inhibi-
tion of sarcomere shortening in sepsis. Confi  rming our in 
vivo data, anti-C5a treatment of septic rats completely re-
versed the sepsis-induced reduction in sarcomere contraction 
and resulted in cardiomyocyte function comparable to that 
found in sham animals. Coupled with our fi  nding of consti-
tutive expression of C5aR on cardiomyocytes and the detri-
mental eff   ect of C5a incubation in vitro on contractility 
parameters, these data strongly suggest that specifi  c  C5a–
C5aR interaction occurs in septic rat cardiomyocytes, lead-
ing to impaired cardiac performance. In agreement with our 
already demonstrated benefi  cial eff  ects of anti-C5a on sur-
vival after CLP (19), improved cardiomyocyte contractility 
resulting in improved end-organ perfusion and oxygen sup-
ply may be the mechanistic cornerstone leading to improved 
survival rates.
Further studies are needed to evaluate intracellular signal-
ing pathways involved after C5a–C5aR interaction in im-
paired myocardial function. Various mediators such as reactive 
oxygen intermediates and proinfl  ammatory cytokines (TNF-
α, IL-1β, IL-6) have been proposed to be myocardial depres-
sant substances underlining that upstream modulation, such as 
interception of the C5a–C5aR interaction, might be useful to 
improve cardiac dysfunction during sepsis (8, 11, 40, 41). Be-
cause intracellular calcium is one of the most important fac-
tors for coordinated and effi   cient contractility, various studies 
have focused on alterations in calcium fl  uxes in cardiomyo-
cytes. It has been suggested that septic cardiomyocyte dys-
function may be linked to altered calcium transient properties 
(39). Recently, an abnormal Ca2+ leakage from the sarcoplas-
mic reticulum has been found and may contribute signifi  -
cantly to the depressed cardiomyocyte shortening in sepsis 
(42). The interaction between phospholamban and sarcoplas-
mic reticulum Ca2+-ATPase2a (SERCA2a), two major mod-
ulators of calcium-dependent contractility, has been shown 
to play a central role in the pathogenesis of congestive heart 
  failure and septic myocardial dysfunction (43, 44). Therefore, 
it is intriguing to hypothesize that C5a–C5aR interaction 
may aff  ect intracellular calcium handling, possibly via modu-
lation of SERCA2a activity leading to functional defi  cits. 
Our in vitro results support this theory. The maximum con-
traction and relaxation velocities are signifi  cantly higher in 
cardiomyocytes from CLP rats treated with anti-C5a when 
compared with infusion of nonspecifi  c IgG. The improved 
contraction and relaxation velocities and peak shortening lev-
els may indicate improved intracellular calcium handling.
There are suggestions that TNFα may contribute to  cardiac 
dysfunction after sepsis or endotoxemic shock (41). After in-
jection of LPS, circulating levels of TNFα reached 10 ng/ml, 
resulting in evidence of cardiac dysfunction (45). Our own 
studies of CLP in rats suggest extremely low levels of TNFα in 
the serum (<5 pg/ml) (46). Accordingly, on the basis of the 
CLP model used in the current studies it seems unlikely that 
TNFα is responsible for the cardiomyocyte defects.
In summary, we have shown that rat cardiomyocytes con-
stitutively express C5aR. We show in vivo and in vitro evi-
dence of the benefi  cial eff  ects of anti-C5a treatment, leading to 
reversal of septic cardiomyopathy. These data indicate a possi-
ble novel and promising approach for the treatment of patients 
with septic cardiomyopathy, using interventions directed ei-
ther at systemic C5a interception or blockade of C5aR.
MATERIALS AND METHODS
Reagents. Unless otherwise indicated, all reagents were purchased from 
Sigma Aldrich.
Experimental animals. Adult male Sprague-Dawley rats (Harlan Inc.) 
weighing 300–350 g were used in all experiments. Animals were housed in 
a specifi  c pathogen-free environment and allowed to acclimate to their sur-
roundings for 1 wk. Standard rat chow and water were available to the ani-
mals during the course of the experiment ad libitum. All experiments were 
performed in accordance with the guidelines set forth by the National Insti-
tutes of Health for Care and Use of Animals. Approval for the experimental 
protocol was obtained from the University Committee on Use and Care of 
Animals at the University of Michigan.
Experimental sepsis. Sepsis was induced by the CLP procedure as de-
scribed previously (31). In brief, rats were anesthetized with isofl  urane (2–
3%, oxygen fl  ow 3L O2/min). After a midline incision, the cecum was 
exposed and ligated  2/3 of the distance from the distal pole. The ligated 
cecum was punctured through and through with an 18-gauge needle and a 
small portion of feces wad expressed. The abdomen was closed in layers us-
ing 4–0 sutures (Ethicon Inc.) and metallic clips. Sham animals underwent 
the same procedure except for ligation and puncture of the cecum. Where 
indicated, animals received 500 μg anti-C5a antibody in 500 μl sterile DPBS 
by intravenous injection immediately after CLP. Control animals received 
a similar dose of nonspecifi  c IgG antibody. Rats were killed at 6, 12, 24, or 
48 h after CLP for in vivo and in vitro experiments.JEM VOL. 203, January 23, 2006  59
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Production of anti-C5a.  The COOH-terminal end (amino residues 58–
77) of the rat C5a molecule was coupled to keyhole limpet hemocyanin and 
was used to immunize goats for the production of anti-sera (47). The poly-
clonal anti-C5a specifi  c antibody was affi   nity purifi  ed, and cross-reactivity 
with rrC5a was confi  rmed in Western blots.
In vivo measurement of LVP. Under isofl  urane anesthesia, the left ca-
rotid artery was exposed, the left vagus nerve was dissected and freed from 
the carotid artery, and microclips were positioned to gain proximal and distal 
vascular control. A 2.5 French microtip catheter (Millar Instruments) was 
inserted into the left carotid artery and advanced into the left ventricle. Cor-
rect positioning in the left ventricle was verifi  ed by fl  uoroscopy and the 
  appearance of the characteristic pressure curve. Mean (LVPmean ), maximum 
(LVPmax ), and minimum (LVPmin ) LVP as well as heart rate (beats per min-
ute) were recorded for 5 min using a signal transduction and amplifi  cation 
system connected to a standard Microsoft Windows operating system PC 
equipped with the appropriate recording and analysis software (PowerLab 
8SP Base, Bridge Amp, Chart 5 Software, ADInstruments).
Isolated perfused hearts (Langendorff   system) and cardiomyocyte 
isolation. CLP or sham-operated rats were anticoagulated using heparin 
sodium (1,000 U i.p.) (Abbott Laboratories) and deeply anesthetized using 
isofl  urane (2–3%) at 12 or 24 h after CLP. After measurement of LVP, the 
heart was rapidly excised and rinsed in ice-cold, sterile Krebs-Henseleit buf-
fer (containing [in mM] 118 NaCl, 4.7 KCl, 21 NaHCO3, 1.8 CaCl2, 1.2 
MgSO4, 1.2 KH2PO4, and 11 glucose, pH 7.40) supplemented with 5 mM 
2-aminoethanesulfonic acid (taurine). The aortic stump was cannulated and 
the heart was mounted on a Langendorff   perfusion system (ADInstruments 
Inc.). Cannulation and initiation of heart perfusion took place within 60 s of 
removal of the organ from the animal. Retrograde perfusion was initiated 
with calcium-containing (1.2 mM) Krebs-Henseleit buff  er for 5 min to sta-
bilize the heart on pump. Flow rate was set to 7.5 ml/min, temperature was 
kept at 38°C (±0.5°C), and perfusion pressure was continuously monitored. 
Perfusion with calcium-free Krebs-Henseleit buff   er was performed for 
3    min, and the fl   ow rate increased to 9.0 ml/min. Collagenase type II 
(Worthington Biochemical Corp.) and hyaluronidase type II were added 
and the hearts were perfused as described previously (48). Cardiomyocytes 
were counted using a hemocytometer, cell viability was assessed by trypan 
blue dye exclusion, and cell morphology. Myocytes with a rod-like shape, 
clearly defi   ned edges and sharp striations were counted as viable cells, 
whereas cells with membrane blebbing, loss of striation pattern and rounded 
cells were classifi  ed as nonviable. Cell suspensions with a viability of >75% 
were used for all subsequent experiments.
Purity of the cardiomyocyte suspension and possible contamination 
with leukocytes (neutrophil granulocytes, lymphocytes, macrophages) was 
assessed with FACScan Flow Cytometry System (Becton Dickinson). Using 
the size of a known reference population of leukocytes for comparison, car-
diomyocytes were gated by size with the typical forward and side light scatter 
profi  les revealing a purity of >99% cardiomyocytes.
Cells were plated onto laminin-coated (Invitrogen), sterile 22 × 22 mm 
glass coverslips at a density of 5 × 104 cells  /  coverslip  /  well. Subsequently, 
coverslips were cultured in six-well tissue culture plates (37°C, 5% CO2) in 
DMEM containing 50 U/ml penicillin, 50 μg/ml streptomycin (pen/strep), 
and 5% fetal calf serum to allow for cell attachment and adhesion to the lam-
inin matrix. Media was then replaced with serum-free M199 media supple-
mented with 10 mM glutathione, 0.2 mg/ml BSA (GIBCO BRL), 15 mM 
Hepes (Sigma-Aldrich), and 26 mM NaHCO3 and placed in an incubator 
(37°C, 5% CO2) for 3 h. All media and other reagents used for the cardio-
myocyte isolation were certifi  ed endotoxin-free by the manufacturers.
Single cell sarcomere contraction and relaxation analysis. Plated  car-
diomyocytes that had been incubated for 3 h underwent single cell sarco-
mere contraction and relaxation analysis using a variable rate CCD video 
camera system (MyoCam, IonOptix Corp.) equipped with sarcomere length 
detection software (IonWizard, IonOptix Corp.). A coverslip with the plated 
cardiomyocytes was placed in a prefabricated chamber, which was fi  lled with 
warm (37°C) M199 and mounted on the microscope system (Eclipse; Nikon 
Corp.) connected to the CCD video camera system. The chamber system 
was connected to a stimulator system (Grass Inc.) and electrical pacing stim-
ulation was initiated (100 mV, 4 ms, 1 Hz). A total number of 1,247 car-
diomyocytes were analyzed. Measurement of cardiomyocyte function, by 
groups, was performed in a randomized fashion if diff  erent experimental 
groups were present. A rectangle-shaped region of interest within each ran-
domly chosen cardiomyocyte was then defi  ned and sarcomeres within the 
focused region were selected for analysis. Typically, this region included 
 15–20 sarcomeres. Cardiomyocyte contractile parameters (relative peak 
sarcomere shortening, normalized maximum contraction velocity −dL/dt, 
normalized maximum relaxation velocity +dL/dt, time of −dL/dt and 
+dL/dt) were recorded for 75 s.
Western blot analysis. Total protein from cardiomyocyte lysates (50 µg, 
harvested 0, 6, 12, 24, or 48 h after CLP or sham operation) was separated 
by electrophoresis in a denaturing 10% polyacrylamide gel and then trans-
ferred to a polyvinylidene fl  uoride membrane. Equal loading was facilitated 
by protein estimation (BCA Protein Assay; Pierce Chemical Co.) and con-
fi  rmed by detection of β-actin as housekeeping protein. Non-specifi  c bind-
ing sites were blocked with TBST (40 mM Tris, pH 7.6; 300 mM NaCl, 
0.1% Tween 20) containing 5% nonfat dry milk for 1 h at 4°C. The mem-
brane was incubated with rabbit anti–rat C5aR antibody at a 1:1,000 dilu-
tion overnight. After fi  ve washes in TBST, the membrane was incubated in 
a 1:5,000 dilution of horseradish peroxidase–conjugated donkey anti–rabbit 
IgG as the secondary antibody (GE Healthcare). The membrane was devel-
oped by enhanced chemiluminescence technique according to the manufac-
turer’s protocol (Fig. 1). The results were quantifi   ed using digital pixel 
density and image analysis software Kodak ID (Scientifi  c Imaging Systems). 
The results were normalized to β-actin and expressed as a ratio of C5aR/β-
actin pixel densities (Fig. 1).
RNA isolation and detection of C5aR mRNA in cardiomyocytes by 
real-time quantitative–PCR analysis.  Rat hearts were obtained 0, 6, 12, 
24, or 48 h after the CLP or sham procedure and cardiomyocytes were iso-
lated as described in previous paragraphs. Total RNA was isolated using the 
TRIzol method (Life Technologies Inc.) according to the manufacturer’s in-
structions. Digestion of any contaminating DNA was achieved by treatment 
of samples with RNase-Free DNase (Promega Corp.). Reverse transcription 
was performed with 5 µg RNA using the Superscript II RNase H− Reverse 
Transcriptase (GIBCO BRL; Life Technologies Inc.) according to the man-
ufacturer’s protocol. Real-time PCR was then performed with primers for 
C5aR: 5′ primer, 5′-T  A  T  A  G  T  C  C  T  G  C  C  C  T  C  G  C  T  C  A  T  -3′; and 3′ primer, 
5′-T  C  A  C  C  A  C  T  T  T  G  A  G  C  G  T  C  T  T  G  G  -3′. The primers were designed for 
409-bp cDNA amplifi  cation in the middle region of the rat C5aR cDNA 
(positions 373–781). The primers for the “housekeeping” gene GAPDH 
were: 5′ primer, 5′-G  C  C  T  C  G  T  C  T  C  A  T  A  G  A  C  A  A  G  A  T  G  -3′; and 3′ primer, 
5′-C  A  G  T  A  G  A  C  T  C  C  A  C  G  A  C  A  T  A  C  -3′. Reactions were prepared in du-
plicates as 50 µl reactions using the iQ SYBR green Supermix reagent (Bio 
Rad Laboratories). After a “hot-start” for 3 min at 94°C, 45 cycles were used 
for amplifi  cation with a melting temperature of 94°C (15 s), an annealing 
temperature of 60°C (15 s), and an extending temperature of 72°C (30 s), 
followed by a melting curve generation starting at 60°C with gradual in-
crease in the temperature up to 95°C in 0.2°C steps. An amplifi  cation plot 
was generated using twofold dilutions of the cDNA generated from a known 
amount (1 μg) of mRNA. The cycle threshold (CT) was set above the base-
line fl  uorescence. Plotting the log of the dilutions versus the CT values then 
generated a standard curve. Quantitation of C5aR and GAPDH in the sam-
ples was determined using the standard curves. Purity of the products was as-
sessed by generating melting curves. Furthermore, the PCR products were 
run out on a 1.2% gel to confi  rm that the amplicons generated were single 
bands at the expected size (unpublished data). The C5aR to GAPDH ratios 
were then plotted for the various time points in CLP and sham rats (Fig. 1). 
Real-time PCR was performed using a Smart cycler (Cepheid). CT  values, 60   ROLE OF C5A IN SEPTIC CARDIAC DYSFUNCTION | Niederbichler et al.
standard curves, and melting curves were generated using the software pro-
vided by the manufacturer (Cepheid).
Incubation of cardiomyocytes with rrC5a. Cardiomyocyte  suspensions 
(5 × 104) isolated 0, 6, 12, 24, or 48 h after CLP or sham procedure were 
incubated with recombinant, endotoxin-free (<5 pg/ml) rat C5a at various 
doses for various times. Dose-dependent eff  ects of C5a on cardiomyocyte 
contractile parameters were then recorded measured and analyzed using the 
MyoCam system.
Confocal microscopy and immunohistochemical staining. Cardio-
myocytes isolated 12 h after CLP or sham injury were plated on coverslips 
and cells were fi  xed with 4% paraformaldehyde. For confocal microscopy, 
nonspecifi  c binding sites were blocked with 0.1% gelatin for 20 min and 
with 4% normal goat serum for 30 min. Cells were incubated with either 
rabbit anti-rat C5aR antibody (1:50 dilution) or preimmune serum (1:50) 
for 2 h, washed, and incubated with goat anti–rabbit Alexa-568 Fab2 (1:200) 
(Invitrogen). After adding SlowFade solution (Invitrogen), cells were visual-
ized using a confocal fl  uorescence microscope. Both projection view and 
optical sections were developed electronically and processed digitally. Opti-
cal scanning and digital processing of the images were performed to deter-
mine the topographic distribution of the Alexa Fluor–conjugated IgG on the 
surface of cardiomyocytes.
For immunohistochemical staining, cardiomyocytes were incubated 
with anti-C5aR antibody in a dilution of 1:100 in PBS for 2 h. After wash-
ing, cells were incubated with a 1:500 diluted peroxidase-conjugated goat 
anti–rabbit IgG for 30 min (Jackson ImmunoResearch Laboratories). After 
washing with PBS for 2 min, cells were stained using the AEC vector stain-
ing kit (Vector Laboratories Inc.) followed by counterstaining with hema-
toxylin for 30 s. Tissue sections were fi  xed and cover slides were mounted 
with Permount medium (Fisher Scientifi  c Co.). Staining was documented 
using light microscopy and digital imaging.
Limulus amebocyte assay. A chromogenic Limulus amebocyte assay 
(QCL-1000, Cambrex Corp.) was performed to confi  rm endotoxin-free cell 
culture conditions. In brief, samples of the cell culture supernatants were mixed 
with the Limulus polyphemus reagent and chromogenic substrate reagent over 
a short incubation period (16 min) and read on a spectrophotometer at a wave-
length of 405 nm. The assay has a sensitivity range of 0.1–1.0 EU/ml.
Statistical analysis. All statistical analysis was performed using STATA 
Statistics/Data Analysis 8.0 software (Stata Corporation). Results are ex-
pressed as the mean value ± SEM unless otherwise noted. ANOVA fol-
lowed by Tukey’s post-hoc tests was used to test for diff  erences among the 
experimental groups for each of the grouping variables. Statistical signifi  -
cance was defi  ned as P ≤ 0.05.
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